KUALA LUMPUR: Drug maker Duopharma Biotech Bhd
said lower demand from private healthcare providers has impacted its results in the third quarter ended Sept 30.
Net profit fell 4% to RM14.2mil, while revenue declined 6.7% to RM133.8mil due to challenging environment faced by private clinics and hospitals amid the current Covid-19 pandemic.
The group, however, said the increased budget allocation to the public healthcare sector by the government.
"This augurs well with the Group as approximately 50% of our sales are to public service sector," it said in a with Bursa Malaysia today.
"In this aspect, we are optimistic that the Healthcare sector will continue to grow in 2020," the company said.
...